Under construction – not a live service

Skip to content

Frontlight Research

Institution

Herlev Hospital

Herlev, DenmarkhealthcareWebsite

Also known as: Amtssygehuset i Herlev

77running trials
43closed trials
0trials confirmed by the site in the last 60 days
–languages not stated

The site has not confirmed any trial yet.

Running trials

Not yet recruiting
Sarcoma and Intra-infusion Exercise for Better Outcomes
NCT07785882· Source
Not yet recruiting
Dose-Escalated Short-Course Proton Therapy for Locally Advanced Rectal Cancer
NCT07903883· Source
Recruiting
Rituximab for Treatment of Checkpoint Inhibitor Induced Immune-related Adverse Events
NCT07694414· Phase 1· Source
Recruiting
A randomised active-controlled study to assess the safety and pharmacodynamics of two blinded doses of vortosiran and open-label apixaban in patients with non-valvular atrial fibrillation
2026-525417-31-00· Phase 2· Source
Recruiting
Fight Osteosarcoma Through European Research Evolving Study Platform From Diagnosis to Relapse
NCT07871864· Phase 3· Source
Recruiting
Feasibility of Automatic, Laser-based Distance Control in Persons With Superficial Bladder Tumors
NCT07860398· Source
Recruiting
A Clinical Study to Compare BupiZenge With Lidocaine for Pain Due to Oral Mucositis in Patients With Head and Neck Cancer.
NCT07672236· Phase 3· Source
Recruiting
Neoadjuvant Immunotherapy for Patients With High-risk Eye Melanoma
NCT07501117· Phase 1· Source
Recruiting
Neoadjuvant nivolumab and ipilimumab for patients with high-risk uveal melanoma
2025-524953-15-00· Phase 1· Source
Recruiting
Crohn’s Head-to-Head Assessing Risankizumab Versus Guselkumab for One Year
2025-521590-13-00· Phase 3· Source
Recruiting
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
NCT07499232· Phase 3· Source
Recruiting
QoLIDia: Quality of Life in Cancer Patients With Diabetes During Immunotherapy
NCT07466212· Source
Recruiting
Comparing Hydrocortisone and Prednisolone for Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD)
NCT06892210· Phase 4· Source
Not yet recruiting
Neoadjuvant Immunotherapy and Organ-sparing Treatment in Patients With Stage I-III dMMR Colon Cancer
NCT07409844· Phase 2· Source
Recruiting
Evaluation of the Role of Luteinizing Hormone (LH) and Human Chorionic Gonadotropin (hCG) in Adult Patients Undergoing Assessment for Endocrine Disorders
NCT07824102· Source
Recruiting
The CPH-MBD Cohort Dietary Substudy - Comparison of Methods for Dietary Registrations
NCT07312981· Source
Recruiting
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT06793215· Phase 3· Source
Recruiting
An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)
NCT07206056· Phase 1/2· Source
Recruiting
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
NCT07144280· Phase 3· Source
Recruiting
[68Ga]Ga-FAPI Total Body PET/CT for Better and Faster Imaging in Cancer
NCT07215182· Phase 2· Source
Recruiting
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
NCT07044336· Phase 3· Source
Recruiting
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
NCT06677060· Phase 3· Source
Recruiting
Phase II randomized study evaluating a Pragmatic approach to Adoptive Cell Therapy (ACT) using an IL2 analog (ANV419/ANV600) vs High dose IL2 after Tumor Infiltrating Lymphocytes (TIL) Therapy in patients with melanoma, NSCLC and cervical cancer. The PragmaTIL
2023-506400-99-00· Phase 2· Source
Recruiting
T-cell Therapy with CRISPR PD1-edited Tumor Infiltrating Lymphocytes for Patients with Metastatic Melanoma
NCT06783270· Phase 1· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)
NCT06534983· Phase 2· Source
Active, not recruiting
Continuous Glucose Monitoring in Dialysis Patients With Diabetes
NCT06641765· Source
Recruiting
Optimal Diuretic Therapies for Acute Heart Failure With Volume Overload
NCT06166654· Phase 3· Source
Recruiting
ADP-TILIL7
2023-509665-20-00· Phase 1· Source
Active, not recruiting
A study comparing TAR-210 versus single agent treatment instilled directly into the bladder in people with bladder cancer with FGFR gene alterations.
2023-507684-19-00· Phase 3· Source
Recruiting
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
NCT06112314· Phase 3· Source
Active, not recruiting
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
NCT06353386· Phase 1/2· Source
Recruiting
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
NCT05485961· Phase 2/3· Source
Recruiting
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
NCT06319820· Phase 3· Source
Recruiting
Integrated Approach in Frail Older People with Atrial Fibrillation
NCT06775028· Source
Active, not recruiting
Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib in Adult Participants With Moderate to Severe Crohn's Disease (CD) in Real World Clinical Practice.
NCT05930275· Source
Recruiting
DESTINY Breast Respond HER2-(Ultra)Low Europe
NCT05945732· Source
Recruiting
DECONGEST-AHF: Vasodilatation or Loop Diuretics in Acute Heart Failure
NCT05276219· Phase 4· Source
Recruiting
Rescue of Nephrons With ALE.F02 (RENAL-F02)
NCT06047171· Phase 2· Source
Recruiting
Does peri-operative treatment with Tranexamic Acid reduce the early relapse rate for patients with melanoma; a randomised controlled trial
2022-502633-26-00· Phase 3· Source
Recruiting
GUIDE.MRD-01-CRC: Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Colorectal Cancer
NCT06111105· Source
Recruiting
DANISH.MRD: Danish Assessment of Minimal Residual Disease by Liquid Biopsies
NCT06076811· Source
Active, not recruiting
A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
NCT05933577· Phase 3· Source
Enrolling by invitation
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Migraine
NCT05707949· Phase 3· Source
Recruiting
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
NCT05711394· Phase 3· Source
Active, not recruiting
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
NCT05757869· Phase 3· Source
Active, not recruiting
IMPROVE-pT1: Accurate Allocation of Completion Resection in Early Colorectal Cancer
NCT06040632· Source
Recruiting
Stroke School -Including Physical Exercise, Patient Education and Individual Follow-up Sessions
NCT04945174· Source
Enrolling by invitation
Translating Genetic Knowledge Into Clinical Care in Non-Autoimmune Diabetes
NCT05368220· Source
Active, not recruiting
The Diverticulitis Study
NCT06023004· Source
Recruiting
A National Phase II Study of Proton Therapy in Hepatocellular Carcinoma
NCT05203120· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Researchers

No researcher is linked here yet.

Closed trials

Completed
ARIISE - ASCs in recently diagnosed non-ischemic heart failure
NCT06840275· Phase 2· Source
Active, not recruiting
Phase 2 Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants with PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
2023-503428-24-00· Phase 2· Source
Active, not recruiting
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
NCT06132958· Phase 3· Source
Completed
A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)
NCT06077864· Phase 3· Source
Completed
Orismilast for the treatment of moderate to severe ulcerative colitis
2022-502763-37-02· Phase 2· Source
Completed
A clinical trial to assess the safety and effects of AGMB-129 compared to placebo in patients with fibrostenotic Crohn’s disease.
2022-502789-26-01· Phase 2· Source
Completed
Phase II, multi‑cohort trial of neoadjuvant and post‑surgery IO102‑IO103 and pembrolizumab in patients with selected resectable tumors
2022-502787-20-00· Phase 2· Source
Completed
STENOVA - A Study to Evaluate Safety, Tolerability, PK and PD of AGMB-129 in Patients With Fibrostenotic Crohn's Disease
NCT05843578· Phase 2· Source
Active, not recruiting
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
NCT05702034· Phase 3· Source
Completed
A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke
NCT05686070· Phase 3· Source
Completed
A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolism in people with irregular and often rapid heartbeat (atrial fibrillation), and at risk for stroke
NCT05643573· Phase 3· Source
Completed
En Bloc Transurethral Resection of Non-muscle Invasive Bladder Cancer
NCT05223491· Source
Completed
Safety and Efficacy of Efavaleukin Alfa in Subjects with Moderately to Severely Active Ulcerative Colitis
NCT04987307· Phase 2· Source
Completed
A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Clinical Activity of RO7276389 Alone and in Combination with Cobimetinib in Participants with BRAF-V600 Mutation-Positive Advanced Solid Tumor or BRAF-V600 Mutation-Positive Melanoma with Central Nervous System Metastases
2023-506310-43-00· Phase 1· Source
Active, not recruiting
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
NCT05173987· Phase 3· Source
Completed
Adjuvant Immunotherapy with Nivolumab + Relatlimab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III-IV Melanoma
NCT05002569· Phase 3· Source
Terminated
The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis
NCT04985968· Phase 3· Source
Completed
A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)
NCT05093933· Phase 3· Source
Completed
A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease
NCT05047263· Phase 3· Source
Completed
AI Augmented Training for Skin Specialists
NCT04758988· Source
Completed
The Cardiac Effects of Empagliflozin in Patients With High Risk of Heart Failure
NCT05084235· Phase 2· Source
Completed
The Metabolic Effects of Empagliflozin in Patients With High Risk of Heart Failure
NCT05042973· Phase 2· Source
Completed
HOLT-ED: Holter-monitoring in End-stage Renal Disease
NCT04876963· Source
Completed
Quantitative ICG Fluorescence Angiography in Colorectal Surgery
NCT05153954· Source
Completed
Cardiac Arrhythmia in Patients With End-Stage Renal Disease
NCT04841304· Source
Completed
When to INDuce for OverWeight? (WINDOW)
NCT04603859· Source
Terminated
A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment
NCT04338269· Phase 3· Source
Completed
Phase 3 Study of Pembrolizumab/Placebo plus Enzalutamide plus ADT in mHSPC
NCT04191096· Phase 3· Source
Active, not recruiting
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)
NCT04008030· Phase 3· Source
Completed
Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)
NCT03924856· Phase 3· Source
Completed
Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
NCT03867084· Phase 3· Source
Completed
Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)
NCT03898180· Phase 3· Source
Completed
Surveillance With PET/CT and Liquid Biopsies of Stage I-III Lung Cancer Patients After Completion of Definitive Therapy
NCT03740126· Source
Completed
A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors
NCT03708328· Phase 1· Source
Completed
A prospective, multicenter, phase-II trial of ibrutinib plus venetoclax in physically fit patients with creatinine clearance ≥ 30 ml/min who have relapsed or refractory chronic lymphocytic leukemia (RR-CLL) with or without TP53 aberrations, HOVON 141 CLL / VIsion Trial of the HOVON and Nordic CLL study groups
NCT03226301· Phase 2· Source
Completed
A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
NCT02975934· Phase 3· Source
Completed
Quality of Life the Danish Multiple Myeloma Patients
NCT02892383· Source
Completed
Colchicine for Prevention of Vascular Inflammation in Non-cardio Embolic Stroke
NCT02898610· Phase 3· Source
Completed
A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)
NCT02684006· Phase 3· Source
Completed
Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)
NCT02231749· Phase 3· Source
Completed
An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors
NCT01968109· Phase 1/2· Source
Completed
Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer
NCT02003924· Phase 3· Source
Completed
A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
NCT01848561· Source

Trial sites

Conditions

Diseases this institution publishes on or runs trials for.

Institution data: ROR 00wys9y90 (CC0-1.0)Updated 10 Nov 2026

Report an error

Under construction, not live – Herlev Hospital: trials and research groups – Frontlight Research